Health Care · Pharmaceutical Preparations

SPRY ARS Pharmaceuticals, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 167185874 filings
Russell 2000

SPRY at a glance

ARS Pharmaceuticals, Inc. (SPRY, SEC CIK 1671858) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ARS Pharmaceuticals, Inc. (SPRY) reported revenue of $84.3 million (down 5.5% from FY2024) and a net loss of $171.3 million. Diluted EPS was -$1.74.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding ARS Pharmaceuticals, Inc. (SPRY) shares worth $87.6 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$84.3M
−5.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
26 funds
$87.6M · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $37.7M, up $5.2M YoY from $32.5M, driven by higher global neffy unit sales
  • Net loss $35.6M vs $51.2M YoY; operating loss $34.2M vs $53.2M
  • Best performer: U.S. neffy product revenue $33.4M vs $31.3M; supply revenue $2.6M vs $1.1M
  • Cash, equivalents and short-term investments $138.4M; operating cash use $139.6M for nine months vs $127.4M
  • Outlook: resources expected sufficient until cash-flow breakeven; Phase 2b ARS-2 interim data expected first quarter 2027

Risk Factors

  • Newly added trade risk: EU-sourced materials face potential pharmaceutical tariffs, with alternative qualification requiring 18-24 months
  • Regulatory risk: Cipla filed paragraph IV challenges in March 2026, prompting ARS to sue in April 2026
  • Commercial risk: Competitor Anaphylm’s NDA resubmission received FDA review, with a March 2027 target action date
  • Financial risk: $125.0 million Credit Agreement balance, plus a $25.0 million minimum liquidity covenant
  • Liquidity risk: Net loss $158.5 million and accumulated deficit $453.1 million as of September 30, 2026

AI summary of the SPRY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Detailed revenue, profitability, cash position and operating updates in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $37.7M, up from $32.5M, with neffy U.S. product revenue $33.4M
  • U.S. neffy market share reached 5%, while field-targeted accounts reached 9% versus 2% in non-targeted accounts
Filed Aug 13, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $33.7M, including $26.2M neffy product revenue versus $12.8M in Q2 2025
  • U.S. neffy market share reached 5%, while field-targeted accounts reached 8% versus 4% in Q2 2025

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed earnings release and financial performance information
Filed Jul 17, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Richard Lowenthal resigned from the Board effective July 15, 2026, tied to severance eligibility
  • Chief Medical Officer Sarina Tanimoto terminated without cause on July 15, 2026

AI summaries of SPRY 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SPRY

Don't miss the next SPRY filing

  • Alerts as it files. A push when SPRY files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SPRY, by share count.
  • Ask anything. An AI agent that reads every SPRY filing and answers with sources.

SPRY alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Slebir John LANov 2, 2026-
Casale DonnAOct 1, 2026-
Smith Margaret EkinsASep 1, 2026-
Casale DonnAJul 1, 2026-
Shah PratikAJun 24, 2026-
SCHNEIDER PHILLIP MAJun 24, 2026-
Shawver LauraAJun 24, 2026-
Kelly MichaelAJun 24, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$89.1M$84.3M
Operating Income--$3.1M-$179.4M
Net Income-$54.4M$8.0M-$171.3M
Op. Margin--3.5%-212.9%
Net Margin-9.0%-203.3%
Balance Sheet
Total Assets$233.2M$351.2M$327.7M
Equity-$256.8M$114.3M
ROE-3.1%-149.9%
Per Share
EPS$-0.57$0.08$-1.74
Cash Flow
Operating CF-$13.5M-$170.9M
CapEx$175K$563K$339K

Source: XBRL data in ARS Pharmaceuticals, Inc. (SPRY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SPRY share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SPRY shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$87.6M
Q2 202627$155.9M
Q1 202626$219.6M
Q4 202523$256.0M
Q3 202523$205.6M
Q2 202525$365.2M
Q1 202523$170.8M
Q4 202418$137.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SPRY filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Nov 4, 2026--
4Oct 5, 2026--
4Sep 2, 2026--
10-QAug 13, 2026Analysis
8-KAug 13, 2026Analysis-
SC 13GJul 27, 2026-
8-KJul 17, 2026Analysis-
8-KJul 7, 2026Analysis-
4Jul 2, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
8-KJun 25, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
10-QMay 15, 2026Analysis
8-KMay 15, 2026Analysis

Related Health Care companies

All Health Care →

SPRY SEC filings: frequently asked questions

Which institutions hold SPRY stock?

As of September 30, 2026, the largest ARS Pharmaceuticals, Inc. (SPRY) holders among the 13F filers tracked by SignalX were BlackRock ($24.1 million), State Street Corp ($15.9 million), Millennium Management ($14.1 million), Vanguard Capital Management LLC ($10.8 million), Citadel Advisors LLC ($4.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SPRY's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ARS Pharmaceuticals, Inc. (SPRY) reported revenue of $84.3 million (down 5.5% from FY2024) and a net loss of $171.3 million. Diluted EPS was -$1.74. The figures come from the XBRL data in the 10-K.

What did SPRY report in its latest 8-K?

ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.

What are the latest SPRY SEC filings?

ARS Pharmaceuticals, Inc. (SPRY) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 4, 2026.

What is SPRY's SEC CIK number?

ARS Pharmaceuticals, Inc. (SPRY)'s SEC Central Index Key (CIK) is 1671858. EDGAR lists every SPRY filing under that number.

Ask anything about SPRY

The research agent reads SPRY's filings, financials, insider trades and 13F holders, then answers with sources.